Following months of speculation, the hybrid Dutch group Akzo Nobel has announced its decision to sell its healthcare business unit following a lucrative $14 billion cash offer from Schering-Plough. The US pharmaceutical company stands to gain access to one of the strongest women's health portfolios in the industry, and a CNS franchise that boasts a potential blockbuster in asenapine.
Edit my basket
© Datamonitor 2014. All rights reserved
Terms & Conditions